{"analyses":[{"ciLowerLimit":"0.71","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.36","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9115","paramType":"Hazard Ratio (HR)","paramValue":"0.98","statisticalMethod":"Wald test"}],"classes":[{"categories":[{"measurements":[{"comment":"Data for upper limit of 95% CI was not reached due to low number (\\<50%) of participants with event of interest.","groupId":"OG000","lowerLimit":"2126","upperLimit":"NA","value":"NA"},{"comment":"Data for median and upper limit of 95% CI were not reached due to low number (\\<50%) of participants with event of interest.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"205"}],"units":"Participants"}],"description":"Event-free survival was defined as the time from randomization to disease progression/relapse, death or initiation of new NHL therapy. If the specified event (progression/relapse, death or new anti-lymphoma treatment) did not occur, event-free survival was censored at the last tumor assessment date either during treatment or follow up. Event-free survival analysis was performed using Kaplan-Meier curves. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 \\& 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to a median of 27 months; up to data cutoff of 31 Oct 2017 \\[up to 6 years\\])","dispersionType":"95% Confidence Interval","groups":[{"description":"Eight cycles of rituximab IV infusion (375 mg/m\\^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\\^2) once every 8 weeks for 24 months.","id":"OG000","title":"Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)"},{"description":"First cycle rituximab IV infusion (375 mg/m\\^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.","id":"OG001","title":"Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)"}],"paramType":"MEDIAN","populationDescription":"ITT population.","reportingStatus":"POSTED","timeFrame":"Baseline up to disease progression or death up to data cutoff of 31 Oct 2017 (up to 6 years) (See detailed timeframe in Outcome Measure description)","title":"Stage I and II (Pooled): Event-Free Survival Assessed Using International Working Group Response Criteria for NHL","type":"SECONDARY","unitOfMeasure":"days"}